Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
ConclusionThis study showed that DP is similar to GP in terms of efficacy and toxicity in treatment of elderly or poor performance patients. Both regimens showed similar grade 3/4 toxicities with different profiles.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Pneumonia | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Taxotere | Thrombocytopenia | Toxicology